img

Global Amyotrophic Lateral Sclerosis (ALS) Industry Research Report, Growth Trends and Competitive Analysis 2024-2034


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Amyotrophic Lateral Sclerosis (ALS) Industry Research Report, Growth Trends and Competitive Analysis 2024-2034

Amyotrophic lateral sclerosis (ALS) is also known as Lou Gehrig’s disease or Maladie De Charcot, it is a neurological disease that causes nerve cells to gradually break down and die.
The cause is not known in 90% to 95% of cases. The remaining 5–10% of cases are inherited from a person's parents. About half of these genetic cases are due to one of two specific genes. The underlying mechanism involves damage to both upper and lower motor neurons. The diagnosis is based on a person's signs and symptoms, with testing done to rule out other potential causes.
The global Amyotrophic Lateral Sclerosis (ALS) market size was US$ 300 million in 2022 and is forecast to a readjusted size of US$ 360.4 million by 2034 with a CAGR of 2.6% during the forecast period 2024-2034.
GlobalAmyotrophic Lateral Sclerosis (ALS) Treatment key players include Mitsubishi Tanabe Pharma, Sanofi, etc. Global top two manufacturers hold a share over 80%.
North America is the largest market, with a share about 60%, followed by Japan, and Europe, both have a share over 20 percent.
In terms of product, Edaravone (Radicava) is the largest segment, with a share over 75%. And in terms of application, the largest application is Hospital, followed by Drugs Store, etc.
In terms of sales (consumption) side, this report focuses on the sales of Amyotrophic Lateral Sclerosis (ALS) by regions (Countries), company, by type and by type. from 2018 to 2024 and forecast to 2034.
The global Amyotrophic Lateral Sclerosis (ALS) market is thoroughly, accurately, and comprehensively assessed in the report with a large focus on market dynamics, market competition, regional growth, segmental analysis, and key growth strategies. Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of sales analysis, the authors of the report have provided reliable estimations and calculations for global revenue and sales by type segment of the global Amyotrophic Lateral Sclerosis (ALS) market. These figures have been provided in terms of both revenue and sales for the period 2018-2034. Additionally, the report provides accurate figures for sales by region in terms of revenue as well as volume for the same period.



By Company


Mitsubishi Tanabe Pharma
Sanofi
Mylan Pharma
Apotex
Glemark Generics
Covis Pharma
Sun Pharma
Lunan Pharma
By Type
Riluzole
Edaravone (Radicava)
Other
By Application
Hospital
Drugs Store
Other
Sales by Region
North America
U.S.
Canada
China
APAC (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Middle East, Africa, Latin America
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2Sales (consumption), revenue of Amyotrophic Lateral Sclerosis (ALS) in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 3Detailed analysis of Amyotrophic Lateral Sclerosis (ALS) manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 7Europe by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 8China by company, by type and by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by company, by type, by application and by region, sales, and revenue for each segment.
Chapter 10Middle East, Africa, and Latin America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 11Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Amyotrophic Lateral Sclerosis (ALS) sales, revenue, price, gross margin, and recent development, etc.
Chapter 12Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14The main points and conclusions of the report.

Table of Content

1 Report Overview
1.1 Amyotrophic Lateral Sclerosis (ALS) Definition
1.2 Market by Type
1.2.1 Global Amyotrophic Lateral Sclerosis (ALS) Market Size Growth Rate by Type, 2018 VS 2022 VS 2034
1.2.2 Riluzole
1.2.3 Edaravone (Radicava)
1.2.4 Other
1.3 Market Segment by Application
1.3.1 Global Amyotrophic Lateral Sclerosis (ALS) Market Size Growth Rate by Application, 2018 VS 2022 VS 2034
1.3.2 Hospital
1.3.3 Drugs Store
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Amyotrophic Lateral Sclerosis (ALS) Sales
2.1 Global Amyotrophic Lateral Sclerosis (ALS) Revenue Estimates and Forecasts 2018-2034
2.2 Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Region: 2018 VS 2022 VS 2034
2.3 Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Region
2.3.1 Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Region (2018-2024)
2.3.2 Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Region (2024-2034)
2.4 Global Amyotrophic Lateral Sclerosis (ALS) Sales Quantity Estimates and Forecasts 2018-2034
2.5 Global Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Region: 2018 VS 2022 VS 2034
2.6 Global Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Region
2.6.1 Global Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Region (2018-2024)
2.6.2 Global Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Region (2024-2034)
2.7 North America
2.8 Europe
2.9 China
2.10 APAC (excluding China)
2.11 Middle East, Africa and Latin America
3 Competition by Manufacturers
3.1 Global Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Manufacturers
3.1.1 Global Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Manufacturers (2018-2024)
3.1.2 Global Amyotrophic Lateral Sclerosis (ALS) Sales Quantity Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Companies by Amyotrophic Lateral Sclerosis (ALS) Sales in 2022
3.2 Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Manufacturers
3.2.1 Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Manufacturers (2018-2024)
3.2.2 Global Amyotrophic Lateral Sclerosis (ALS) Revenue Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by Amyotrophic Lateral Sclerosis (ALS) Revenue in 2022
3.3 Global Amyotrophic Lateral Sclerosis (ALS) Sales Price by Manufacturers
3.4 Global Key Players of Amyotrophic Lateral Sclerosis (ALS), Industry Ranking, 2021 VS 2022
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Amyotrophic Lateral Sclerosis (ALS) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Amyotrophic Lateral Sclerosis (ALS), Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Amyotrophic Lateral Sclerosis (ALS), Product Offered and Application
3.8 Global Key Manufacturers of Amyotrophic Lateral Sclerosis (ALS), Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Estimates and Forecasts by Type
4.1 Global Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Type
4.1.1 Global Amyotrophic Lateral Sclerosis (ALS) Historical Sales Quantity by Type (2018-2024)
4.1.2 Global Amyotrophic Lateral Sclerosis (ALS) Forecasted Sales Quantity by Type (2024-2034)
4.1.3 Global Amyotrophic Lateral Sclerosis (ALS) Sales Quantity Market Share by Type (2018-2034)
4.2 Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Type
4.2.1 Global Amyotrophic Lateral Sclerosis (ALS) Historical Revenue by Type (2018-2024)
4.2.2 Global Amyotrophic Lateral Sclerosis (ALS) Forecasted Revenue by Type (2024-2034)
4.2.3 Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Type (2018-2034)
4.3 Global Amyotrophic Lateral Sclerosis (ALS) Price by Type
4.3.1 Global Amyotrophic Lateral Sclerosis (ALS) Price by Type (2018-2024)
4.3.2 Global Amyotrophic Lateral Sclerosis (ALS) Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Application
5.1.1 Global Amyotrophic Lateral Sclerosis (ALS) Historical Sales Quantity by Application (2018-2024)
5.1.2 Global Amyotrophic Lateral Sclerosis (ALS) Forecasted Sales Quantity by Application (2024-2034)
5.1.3 Global Amyotrophic Lateral Sclerosis (ALS) Sales Quantity Market Share by Application (2018-2034)
5.2 Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Application
5.2.1 Global Amyotrophic Lateral Sclerosis (ALS) Historical Revenue by Application (2018-2024)
5.2.2 Global Amyotrophic Lateral Sclerosis (ALS) Forecasted Revenue by Application (2024-2034)
5.2.3 Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Application (2018-2034)
5.3 Global Amyotrophic Lateral Sclerosis (ALS) Price by Application
5.3.1 Global Amyotrophic Lateral Sclerosis (ALS) Price by Application (2018-2024)
5.3.2 Global Amyotrophic Lateral Sclerosis (ALS) Price Forecast by Application (2024-2034)
6 North America
6.1 North America Amyotrophic Lateral Sclerosis (ALS) Sales by Company
6.1.1 North America Amyotrophic Lateral Sclerosis (ALS) Revenue by Company (2018-2024)
6.1.2 North America Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Company (2018-2024)
6.2 North America Amyotrophic Lateral Sclerosis (ALS) Market Size by Type
6.2.1 North America Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Type (2018-2034)
6.2.2 North America Amyotrophic Lateral Sclerosis (ALS) Revenue by Type (2018-2034)
6.3 North America Amyotrophic Lateral Sclerosis (ALS) Market Size by Application
6.3.1 North America Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Application (2018-2034)
6.3.2 North America Amyotrophic Lateral Sclerosis (ALS) Revenue by Application (2018-2034)
6.4 North America Amyotrophic Lateral Sclerosis (ALS) Market Size by Country
6.4.1 North America Amyotrophic Lateral Sclerosis (ALS) Revenue by Country: 2018 VS 2022 VS 2034
6.4.2 North America Amyotrophic Lateral Sclerosis (ALS) Revenue by Country (2018-2034)
6.4.3 North America Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Country (2018-2034)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Amyotrophic Lateral Sclerosis (ALS) Sales by Company
7.1.1 Europe Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Company (2018-2024)
7.1.2 Europe Amyotrophic Lateral Sclerosis (ALS) Revenue by Company (2018-2024)
7.2 Europe Amyotrophic Lateral Sclerosis (ALS) Market Size by Type
7.2.1 Europe Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Type (2018-2034)
7.2.2 Europe Amyotrophic Lateral Sclerosis (ALS) Revenue by Type (2018-2034)
7.3 Europe Amyotrophic Lateral Sclerosis (ALS) Market Size by Application
7.3.1 Europe Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Application (2018-2034)
7.3.2 Europe Amyotrophic Lateral Sclerosis (ALS) Revenue by Application (2018-2034)
7.4 Europe Amyotrophic Lateral Sclerosis (ALS) Market Size by Country
7.4.1 Europe Amyotrophic Lateral Sclerosis (ALS) Revenue by Country: 2018 VS 2022 VS 2034
7.4.2 Europe Amyotrophic Lateral Sclerosis (ALS) Revenue by Country (2018-2034)
7.4.3 Europe Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Country (2018-2034)
7.4.4 Germany
7.4.5 France
7.4.6 U.K.
7.4.7 Italy
7.4.8 Russia
8 China
8.1 China Amyotrophic Lateral Sclerosis (ALS) Sales by Company
8.1.1 China Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Company (2018-2024)
8.1.2 China Amyotrophic Lateral Sclerosis (ALS) Revenue by Company (2018-2024)
8.2 China Amyotrophic Lateral Sclerosis (ALS) Market Size by Type
8.2.1 China Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Type (2018-2034)
8.2.2 China Amyotrophic Lateral Sclerosis (ALS) Revenue by Type (2018-2034)
8.3 China Amyotrophic Lateral Sclerosis (ALS) Market Size by Application
8.3.1 China Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Application (2018-2034)
8.3.2 China Amyotrophic Lateral Sclerosis (ALS) Revenue by Application (2018-2034)
9 APAC (excluding China)
9.1 APAC Amyotrophic Lateral Sclerosis (ALS) Sales by Company
9.1.1 APAC Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Company (2018-2024)
9.1.2 APAC Amyotrophic Lateral Sclerosis (ALS) Revenue by Company (2018-2024)
9.2 APAC Amyotrophic Lateral Sclerosis (ALS) Market Size by Type
9.2.1 APAC Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Type (2018-2034)
9.2.2 APAC Amyotrophic Lateral Sclerosis (ALS) Revenue by Type (2018-2034)
9.3 APAC Amyotrophic Lateral Sclerosis (ALS) Market Size by Application
9.3.1 APAC Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Application (2018-2034)
9.3.2 APAC Amyotrophic Lateral Sclerosis (ALS) Revenue by Application (2018-2034)
9.4 APAC Amyotrophic Lateral Sclerosis (ALS) Market Size by Region
9.4.1 APAC Amyotrophic Lateral Sclerosis (ALS) Revenue by Region: 2018 VS 2022 VS 2034
9.4.2 APAC Amyotrophic Lateral Sclerosis (ALS) Revenue by Region (2018-2034)
9.4.3 APAC Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Region (2018-2034)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Amyotrophic Lateral Sclerosis (ALS) Sales by Company
10.1.1 Middle East, Africa and Latin America Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Company (2018-2024)
10.1.2 Middle East, Africa and Latin America Amyotrophic Lateral Sclerosis (ALS) Revenue by Company (2018-2024)
10.2 Middle East, Africa and Latin America Amyotrophic Lateral Sclerosis (ALS) Market Size by Type
10.2.1 Middle East, Africa and Latin America Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Type (2018-2034)
10.2.2 Middle East, Africa and Latin America Amyotrophic Lateral Sclerosis (ALS) Revenue by Type (2018-2034)
10.3 Middle East, Africa and Latin America Amyotrophic Lateral Sclerosis (ALS) Market Size by Application
10.3.1 Middle East, Africa and Latin America Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Application (2018-2034)
10.3.2 Middle East, Africa and Latin America Amyotrophic Lateral Sclerosis (ALS) Revenue by Application (2018-2034)
10.4 Middle East, Africa and Latin America Amyotrophic Lateral Sclerosis (ALS) Market Size by Country
10.4.1 Middle East, Africa and Latin America Amyotrophic Lateral Sclerosis (ALS) Revenue by Country: 2018 VS 2022 VS 2034
10.4.2 Middle East, Africa and Latin America Amyotrophic Lateral Sclerosis (ALS) Revenue by Country (2018-2034)
10.4.3 Middle East, Africa and Latin America Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Country (2018-2034)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Israel
10.4.8 GCC Countries
11 Company Profiles
11.1 Mitsubishi Tanabe Pharma
11.1.1 Mitsubishi Tanabe Pharma Company Information
11.1.2 Mitsubishi Tanabe Pharma Overview
11.1.3 Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.1.4 Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Products and Services
11.1.5 Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) SWOT Analysis
11.1.6 Mitsubishi Tanabe Pharma Recent Developments
11.2 Sanofi
11.2.1 Sanofi Company Information
11.2.2 Sanofi Overview
11.2.3 Sanofi Amyotrophic Lateral Sclerosis (ALS) Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.2.4 Sanofi Amyotrophic Lateral Sclerosis (ALS) Products and Services
11.2.5 Sanofi Amyotrophic Lateral Sclerosis (ALS) SWOT Analysis
11.2.6 Sanofi Recent Developments
11.3 Mylan Pharma
11.3.1 Mylan Pharma Company Information
11.3.2 Mylan Pharma Overview
11.3.3 Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.3.4 Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Products and Services
11.3.5 Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) SWOT Analysis
11.3.6 Mylan Pharma Recent Developments
11.4 Apotex
11.4.1 Apotex Company Information
11.4.2 Apotex Overview
11.4.3 Apotex Amyotrophic Lateral Sclerosis (ALS) Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.4.4 Apotex Amyotrophic Lateral Sclerosis (ALS) Products and Services
11.4.5 Apotex Amyotrophic Lateral Sclerosis (ALS) SWOT Analysis
11.4.6 Apotex Recent Developments
11.5 Glemark Generics
11.5.1 Glemark Generics Company Information
11.5.2 Glemark Generics Overview
11.5.3 Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.5.4 Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Products and Services
11.5.5 Glemark Generics Amyotrophic Lateral Sclerosis (ALS) SWOT Analysis
11.5.6 Glemark Generics Recent Developments
11.6 Covis Pharma
11.6.1 Covis Pharma Company Information
11.6.2 Covis Pharma Overview
11.6.3 Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.6.4 Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Products and Services
11.6.5 Covis Pharma Amyotrophic Lateral Sclerosis (ALS) SWOT Analysis
11.6.6 Covis Pharma Recent Developments
11.7 Sun Pharma
11.7.1 Sun Pharma Company Information
11.7.2 Sun Pharma Overview
11.7.3 Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.7.4 Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Products and Services
11.7.5 Sun Pharma Amyotrophic Lateral Sclerosis (ALS) SWOT Analysis
11.7.6 Sun Pharma Recent Developments
11.8 Lunan Pharma
11.8.1 Lunan Pharma Company Information
11.8.2 Lunan Pharma Overview
11.8.3 Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.8.4 Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Products and Services
11.8.5 Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) SWOT Analysis
11.8.6 Lunan Pharma Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Amyotrophic Lateral Sclerosis (ALS) Value Chain Analysis
12.2 Amyotrophic Lateral Sclerosis (ALS) Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Amyotrophic Lateral Sclerosis (ALS) Production Mode & Process
12.4 Amyotrophic Lateral Sclerosis (ALS) Sales and Marketing
12.4.1 Amyotrophic Lateral Sclerosis (ALS) Sales Channels
12.4.2 Amyotrophic Lateral Sclerosis (ALS) Distributors
12.5 Amyotrophic Lateral Sclerosis (ALS) Customers
13 Market Dynamics
13.1 Amyotrophic Lateral Sclerosis (ALS) Industry Trends
13.2 Amyotrophic Lateral Sclerosis (ALS) Market Drivers
13.3 Amyotrophic Lateral Sclerosis (ALS) Market Challenges
13.4 Amyotrophic Lateral Sclerosis (ALS) Market Restraints
14 Key Findings
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Amyotrophic Lateral Sclerosis (ALS) Market Size Growth Rate (CAGR) by Type, 2018 VS 2022 VS 2034 (US$ Million)
Table 2. Major Manufacturers of Riluzole
Table 3. Major Manufacturers of Edaravone (Radicava)
Table 4. Major Manufacturers of Other
Table 5. Global Amyotrophic Lateral Sclerosis (ALS) Market Size Growth Rate (CAGR) by Application, 2018 VS 2022 VS 2034 (US$ Million)
Table 6. Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 7. Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Region (2018-2024) & (US$ Million)
Table 8. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Region (2018-2024)
Table 9. Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Region (2024-2034) & (US$ Million)
Table 10. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Region (2024-2034)
Table 11. Global Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Region: 2018 VS 2022 VS 2034 (K MT)
Table 12. Global Amyotrophic Lateral Sclerosis (ALS) Sales by Region (2018-2024) & (K MT)
Table 13. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Region (2018-2024)
Table 14. Global Amyotrophic Lateral Sclerosis (ALS) Sales by Region (2024-2034) & (K MT)
Table 15. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Region (2024-2034)
Table 16. Global Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Manufacturers (2018-2024) & (K MT)
Table 17. Global Amyotrophic Lateral Sclerosis (ALS) Sales Quantity Share by Manufacturers (2018-2024)
Table 18. Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 19. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Share by Manufacturers (2018-2024)
Table 20. Global Amyotrophic Lateral Sclerosis (ALS) Price by Manufacturers 2018-2024 (USD/MT)
Table 21. Global Key Players of Amyotrophic Lateral Sclerosis (ALS), Industry Ranking, 2021 VS 2022
Table 22. Global Amyotrophic Lateral Sclerosis (ALS) Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 23. Global Amyotrophic Lateral Sclerosis (ALS) by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Amyotrophic Lateral Sclerosis (ALS) as of 2022)
Table 24. Global Key Manufacturers of Amyotrophic Lateral Sclerosis (ALS), Manufacturing Base Distribution and Headquarters
Table 25. Global Key Manufacturers of Amyotrophic Lateral Sclerosis (ALS), Product Offered and Application
Table 26. Global Key Manufacturers of Amyotrophic Lateral Sclerosis (ALS), Date of Enter into This Industry
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Type (2018-2024) & (K MT)
Table 29. Global Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Type (2024-2034) & (K MT)
Table 30. Global Amyotrophic Lateral Sclerosis (ALS) Sales Quantity Share by Type (2018-2024)
Table 31. Global Amyotrophic Lateral Sclerosis (ALS) Sales Quantity Share by Type (2024-2034)
Table 32. Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Type (2018-2024) & (US$ Million)
Table 33. Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Type (2024-2034) & (US$ Million)
Table 34. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Share by Type (2018-2024)
Table 35. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Share by Type (2024-2034)
Table 36. Amyotrophic Lateral Sclerosis (ALS) Price by Type (2018-2024) & (USD/MT)
Table 37. Global Amyotrophic Lateral Sclerosis (ALS) Price Forecast by Type (2024-2034) & (USD/MT)
Table 38. Global Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Application (2018-2024) & (K MT)
Table 39. Global Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Application (2024-2034) & (K MT)
Table 40. Global Amyotrophic Lateral Sclerosis (ALS) Sales Quantity Share by Application (2018-2024)
Table 41. Global Amyotrophic Lateral Sclerosis (ALS) Sales Quantity Share by Application (2024-2034)
Table 42. Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Application (2018-2024) & (US$ Million)
Table 43. Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Application (2024-2034) & (US$ Million)
Table 44. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Share by Application (2018-2024)
Table 45. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Share by Application (2024-2034)
Table 46. Amyotrophic Lateral Sclerosis (ALS) Price by Application (2018-2024) & (USD/MT)
Table 47. Global Amyotrophic Lateral Sclerosis (ALS) Price Forecast by Application (2024-2034) & (USD/MT)
Table 48. North America Amyotrophic Lateral Sclerosis (ALS) Revenue by Company (2018-2024) & (US$ Million)
Table 49. North America Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Company (2018-2024) & (K MT)
Table 50. North America Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Type (2018-2024) & (K MT)
Table 51. North America Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Type (2024-2034) & (K MT)
Table 52. North America Amyotrophic Lateral Sclerosis (ALS) Revenue by Type (2018-2024) & (US$ Million)
Table 53. North America Amyotrophic Lateral Sclerosis (ALS) Revenue by Type (2024-2034) & (US$ Million)
Table 54. North America Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Application (2018-2024) & (K MT)
Table 55. North America Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Application (2024-2034) & (K MT)
Table 56. North America Amyotrophic Lateral Sclerosis (ALS) Revenue by Application (2018-2024) & (US$ Million)
Table 57. North America Amyotrophic Lateral Sclerosis (ALS) Revenue by Application (2024-2034) & (US$ Million)
Table 58. North America Amyotrophic Lateral Sclerosis (ALS) Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 59. North America Amyotrophic Lateral Sclerosis (ALS) Revenue by Country (2018-2024) & (US$ Million)
Table 60. North America Amyotrophic Lateral Sclerosis (ALS) Revenue by Country (2024-2034) & (US$ Million)
Table 61. North America Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Country (2018-2024) & (K MT)
Table 62. North America Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Country (2024-2034) & (K MT)
Table 63. Europe Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Company (2018-2024) & (K MT)
Table 64. Europe Amyotrophic Lateral Sclerosis (ALS) Revenue by Company (2018-2024) & (US$ Million)
Table 65. Europe Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Type (2018-2024) & (K MT)
Table 66. Europe Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Type (2024-2034) & (K MT)
Table 67. Europe Amyotrophic Lateral Sclerosis (ALS) Revenue by Type (2018-2024) & (US$ Million)
Table 68. Europe Amyotrophic Lateral Sclerosis (ALS) Revenue by Type (2024-2034) & (US$ Million)
Table 69. Europe Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Application (2018-2024) & (K MT)
Table 70. Europe Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Application (2024-2034) & (K MT)
Table 71. Europe Amyotrophic Lateral Sclerosis (ALS) Revenue by Application (2018-2024) & (US$ Million)
Table 72. Europe Amyotrophic Lateral Sclerosis (ALS) Revenue by Application (2024-2034) & (US$ Million)
Table 73. Europe Amyotrophic Lateral Sclerosis (ALS) Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 74. Europe Amyotrophic Lateral Sclerosis (ALS) Revenue by Country (2018-2024) & (US$ Million)
Table 75. Europe Amyotrophic Lateral Sclerosis (ALS) Revenue by Country (2024-2034) & (US$ Million)
Table 76. Europe Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Country (2018-2024) & (K MT)
Table 77. Europe Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Country (2024-2034) & (K MT)
Table 78. China Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Company (2018-2024) & (K MT)
Table 79. China Amyotrophic Lateral Sclerosis (ALS) Revenue by Company (2018-2024) & (US$ Million)
Table 80. China Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Type (2018-2024) & (K MT)
Table 81. China Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Type (2024-2034) & (K MT)
Table 82. China Amyotrophic Lateral Sclerosis (ALS) Revenue by Type (2018-2024) & (US$ Million)
Table 83. China Amyotrophic Lateral Sclerosis (ALS) Revenue by Type (2024-2034) & (US$ Million)
Table 84. China Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Application (2018-2024) & (K MT)
Table 85. China Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Application (2024-2034) & (K MT)
Table 86. China Amyotrophic Lateral Sclerosis (ALS) Revenue by Application (2018-2024) & (US$ Million)
Table 87. China Amyotrophic Lateral Sclerosis (ALS) Revenue by Application (2024-2034) & (US$ Million)
Table 88. APAC Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Company (2018-2024) & (K MT)
Table 89. APAC Amyotrophic Lateral Sclerosis (ALS) Revenue by Company (2018-2024) & (US$ Million)
Table 90. APAC Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Type (2018-2024) & (K MT)
Table 91. APAC Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Type (2024-2034) & (K MT)
Table 92. APAC Amyotrophic Lateral Sclerosis (ALS) Revenue by Type (2018-2024) & (US$ Million)
Table 93. APAC Amyotrophic Lateral Sclerosis (ALS) Revenue by Type (2024-2034) & (US$ Million)
Table 94. APAC Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Application (2018-2024) & (K MT)
Table 95. APAC Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Application (2024-2034) & (K MT)
Table 96. APAC Amyotrophic Lateral Sclerosis (ALS) Revenue by Application (2018-2024) & (US$ Million)
Table 97. APAC Amyotrophic Lateral Sclerosis (ALS) Revenue by Application (2024-2034) & (US$ Million)
Table 98. APAC Amyotrophic Lateral Sclerosis (ALS) Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 99. APAC Amyotrophic Lateral Sclerosis (ALS) Revenue by Region (2018-2024) & (US$ Million)
Table 100. APAC Amyotrophic Lateral Sclerosis (ALS) Revenue by Region (2024-2034) & (US$ Million)
Table 101. APAC Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Region (2018-2024) & (K MT)
Table 102. APAC Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Region (2024-2034) & (K MT)
Table 103. Middle East, Africa and Latin America Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Company (2018-2024) & (K MT)
Table 104. Middle East, Africa and Latin America Amyotrophic Lateral Sclerosis (ALS) Revenue by Company (2018-2024) & (US$ Million)
Table 105. Middle East, Africa and Latin America Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Type (2018-2024) & (K MT)
Table 106. Middle East, Africa and Latin America Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Type (2024-2034) & (K MT)
Table 107. Middle East, Africa and Latin America Amyotrophic Lateral Sclerosis (ALS) Revenue by Type (2018-2024) & (US$ Million)
Table 108. Middle East, Africa and Latin America Amyotrophic Lateral Sclerosis (ALS) Revenue by Type (2024-2034) & (US$ Million)
Table 109. Middle East, Africa and Latin America Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Application (2018-2024) & (K MT)
Table 110. Middle East, Africa and Latin America Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Application (2024-2034) & (K MT)
Table 111. Middle East, Africa and Latin America Amyotrophic Lateral Sclerosis (ALS) Revenue by Application (2018-2024) & (US$ Million)
Table 112. Middle East, Africa and Latin America Amyotrophic Lateral Sclerosis (ALS) Revenue by Application (2024-2034) & (US$ Million)
Table 113. Middle East, Africa and Latin America Amyotrophic Lateral Sclerosis (ALS) Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 114. Middle East, Africa and Latin America Amyotrophic Lateral Sclerosis (ALS) Revenue by Country (2018-2024) & (US$ Million)
Table 115. Middle East, Africa and Latin America Amyotrophic Lateral Sclerosis (ALS) Revenue by Country (2024-2034) & (US$ Million)
Table 116. Middle East, Africa and Latin America Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Country (2018-2024) & (K MT)
Table 117. Middle East, Africa and Latin America Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Country (2024-2034) & (K MT)
Table 118. Mitsubishi Tanabe Pharma Company Information
Table 119. Mitsubishi Tanabe Pharma Description and Overview
Table 120. Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Sales Quantity (K MT), Revenue (US$ Million), Average Selling Price (ASP) (USD/MT) and Gross Margin (2018-2024)
Table 121. Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Product and Services
Table 122. Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) SWOT Analysis
Table 123. Mitsubishi Tanabe Pharma Recent Developments
Table 124. Sanofi Company Information
Table 125. Sanofi Description and Overview
Table 126. Sanofi Amyotrophic Lateral Sclerosis (ALS) Sales Quantity (K MT), Revenue (US$ Million), Average Selling Price (ASP) (USD/MT) and Gross Margin (2018-2024)
Table 127. Sanofi Amyotrophic Lateral Sclerosis (ALS) Product and Services
Table 128. Sanofi Amyotrophic Lateral Sclerosis (ALS) SWOT Analysis
Table 129. Sanofi Recent Developments
Table 130. Mylan Pharma Company Information
Table 131. Mylan Pharma Description and Overview
Table 132. Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Sales Quantity (K MT), Revenue (US$ Million), Average Selling Price (ASP) (USD/MT) and Gross Margin (2018-2024)
Table 133. Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Product and Services
Table 134. Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) SWOT Analysis
Table 135. Mylan Pharma Recent Developments
Table 136. Apotex Company Information
Table 137. Apotex Description and Overview
Table 138. Apotex Amyotrophic Lateral Sclerosis (ALS) Sales Quantity (K MT), Revenue (US$ Million), Average Selling Price (ASP) (USD/MT) and Gross Margin (2018-2024)
Table 139. Apotex Amyotrophic Lateral Sclerosis (ALS) Product and Services
Table 140. Apotex Amyotrophic Lateral Sclerosis (ALS) SWOT Analysis
Table 141. Apotex Recent Developments
Table 142. Glemark Generics Company Information
Table 143. Glemark Generics Description and Overview
Table 144. Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Sales Quantity (K MT), Revenue (US$ Million), Average Selling Price (ASP) (USD/MT) and Gross Margin (2018-2024)
Table 145. Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Product and Services
Table 146. Glemark Generics Amyotrophic Lateral Sclerosis (ALS) SWOT Analysis
Table 147. Glemark Generics Recent Developments
Table 148. Covis Pharma Company Information
Table 149. Covis Pharma Description and Overview
Table 150. Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Sales Quantity (K MT), Revenue (US$ Million), Average Selling Price (ASP) (USD/MT) and Gross Margin (2018-2024)
Table 151. Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Product and Services
Table 152. Covis Pharma Amyotrophic Lateral Sclerosis (ALS) SWOT Analysis
Table 153. Covis Pharma Recent Developments
Table 154. Sun Pharma Company Information
Table 155. Sun Pharma Description and Overview
Table 156. Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Sales Quantity (K MT), Revenue (US$ Million), Average Selling Price (ASP) (USD/MT) and Gross Margin (2018-2024)
Table 157. Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Product and Services
Table 158. Sun Pharma Amyotrophic Lateral Sclerosis (ALS) SWOT Analysis
Table 159. Sun Pharma Recent Developments
Table 160. Lunan Pharma Company Information
Table 161. Lunan Pharma Description and Overview
Table 162. Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Sales Quantity (K MT), Revenue (US$ Million), Average Selling Price (ASP) (USD/MT) and Gross Margin (2018-2024)
Table 163. Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Product and Services
Table 164. Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) SWOT Analysis
Table 165. Lunan Pharma Recent Developments
Table 166. Key Raw Materials Lists
Table 167. Raw Materials Key Suppliers Lists
Table 168. Amyotrophic Lateral Sclerosis (ALS) Distributors List
Table 169. Amyotrophic Lateral Sclerosis (ALS) Customers List
Table 170. Amyotrophic Lateral Sclerosis (ALS) Market Trends
Table 171. Amyotrophic Lateral Sclerosis (ALS) Market Drivers
Table 172. Amyotrophic Lateral Sclerosis (ALS) Market Challenges
Table 173. Amyotrophic Lateral Sclerosis (ALS) Market Restraints
Table 174. Research Programs/Design for This Report
Table 175. Key Data Information from Secondary Sources
Table 176. Key Data Information from Primary Sources
List of Figures
Figure 1. Amyotrophic Lateral Sclerosis (ALS) Product Picture
Figure 2. Global Amyotrophic Lateral Sclerosis (ALS) Market Size Growth Rate by Type, 2018 VS 2022 VS 2034 (US$ Million)
Figure 3. Global Amyotrophic Lateral Sclerosis (ALS) Market Share by Type in 2022 & 2034
Figure 4. Riluzole Product Picture
Figure 5. Edaravone (Radicava) Product Picture
Figure 6. Other Product Picture
Figure 7. Global Amyotrophic Lateral Sclerosis (ALS) Market Size Growth Rate by Application, 2018 VS 2022 VS 2034 (US$ Million)
Figure 8. Global Amyotrophic Lateral Sclerosis (ALS) Market Share by Application in 2022 & 2034
Figure 9. Hospital
Figure 10. Drugs Store
Figure 11. Other
Figure 12. Amyotrophic Lateral Sclerosis (ALS) Report Years Considered
Figure 13. Global Amyotrophic Lateral Sclerosis (ALS) Revenue, (US$ Million), 2018 VS 2022 VS 2034
Figure 14. Global Amyotrophic Lateral Sclerosis (ALS) Revenue 2018-2034 (US$ Million)
Figure 15. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Region in Percentage: 2022 Versus 2034
Figure 16. Global Amyotrophic Lateral Sclerosis (ALS) Sales Quantity 2018-2034 (K MT)
Figure 17. Global Amyotrophic Lateral Sclerosis (ALS) Sales Quantity Market Share by Region (2018-2024)
Figure 18. Global Amyotrophic Lateral Sclerosis (ALS) Sales Quantity Market Share by Region (2024-2034)
Figure 19. North America Amyotrophic Lateral Sclerosis (ALS) Sales Quantity YoY (2018-2034) & (K MT)
Figure 20. North America Amyotrophic Lateral Sclerosis (ALS) Revenue YoY (2018-2034) & (US$ Million)
Figure 21. Europe Amyotrophic Lateral Sclerosis (ALS) Sales Quantity YoY (2018-2034) & (K MT)
Figure 22. Europe Amyotrophic Lateral Sclerosis (ALS) Revenue YoY (2018-2034) & (US$ Million)
Figure 23. China Amyotrophic Lateral Sclerosis (ALS) Sales Quantity YoY (2018-2034) & (K MT)
Figure 24. China Amyotrophic Lateral Sclerosis (ALS) Revenue YoY (2018-2034) & (US$ Million)
Figure 25. APAC Amyotrophic Lateral Sclerosis (ALS) Sales Quantity YoY (2018-2034) & (K MT)
Figure 26. APAC Amyotrophic Lateral Sclerosis (ALS) Revenue YoY (2018-2034) & (US$ Million)
Figure 27. Middle East, Africa and Latin America Amyotrophic Lateral Sclerosis (ALS) Sales Quantity YoY (2018-2034) & (K MT)
Figure 28. Middle East, Africa and Latin America Amyotrophic Lateral Sclerosis (ALS) Revenue YoY (2018-2034) & (US$ Million)
Figure 29. The Top 10 and Top 5 Players Market Share by Amyotrophic Lateral Sclerosis (ALS) Sales Quantity in 2022
Figure 30. The Top 10 and Top 5 Players Market Share by Amyotrophic Lateral Sclerosis (ALS) Revenue in 2022
Figure 31. Amyotrophic Lateral Sclerosis (ALS) Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 32. Global Amyotrophic Lateral Sclerosis (ALS) Sales Quantity Market Share by Type (2018-2034)
Figure 33. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Type (2018-2034)
Figure 34. Global Amyotrophic Lateral Sclerosis (ALS) Sales Quantity Market Share by Application (2018-2034)
Figure 35. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Application (2018-2034)
Figure 36. North America Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Company in 2022
Figure 37. North America Amyotrophic Lateral Sclerosis (ALS) Sales Quantity Market Share by Company in 2022
Figure 38. North America Amyotrophic Lateral Sclerosis (ALS) Sales Quantity Market Share by Type (2018-2034)
Figure 39. North America Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Type (2018-2034)
Figure 40. North America Amyotrophic Lateral Sclerosis (ALS) Sales Quantity Market Share by Application (2018-2034)
Figure 41. North America Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Application (2018-2034)
Figure 42. North America Amyotrophic Lateral Sclerosis (ALS) Revenue Share by Country (2018-2034)
Figure 43. North America Amyotrophic Lateral Sclerosis (ALS) Sales Quantity Share by Country (2018-2034)
Figure 44. U.S. Amyotrophic Lateral Sclerosis (ALS) Revenue (2018-2034) & (US$ Million)
Figure 45. Canada Amyotrophic Lateral Sclerosis (ALS) Revenue (2018-2034) & (US$ Million)
Figure 46. Europe Amyotrophic Lateral Sclerosis (ALS) Sales Quantity Market Share by Company in 2022
Figure 47. Europe Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Company in 2022
Figure 48. Europe Amyotrophic Lateral Sclerosis (ALS) Sales Quantity Market Share by Type (2018-2034)
Figure 49. Europe Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Type (2018-2034)
Figure 50. Europe Amyotrophic Lateral Sclerosis (ALS) Sales Quantity Market Share by Application (2018-2034)
Figure 51. Europe Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Application (2018-2034)
Figure 52. Europe Amyotrophic Lateral Sclerosis (ALS) Revenue Share by Country (2018-2034)
Figure 53. Europe Amyotrophic Lateral Sclerosis (ALS) Sales Quantity Share by Country (2018-2034)
Figure 54. Germany Amyotrophic Lateral Sclerosis (ALS) Revenue (2018-2034) & (US$ Million)
Figure 55. France Amyotrophic Lateral Sclerosis (ALS) Revenue (2018-2034) & (US$ Million)
Figure 56. U.K. Amyotrophic Lateral Sclerosis (ALS) Revenue (2018-2034) & (US$ Million)
Figure 57. Italy Amyotrophic Lateral Sclerosis (ALS) Revenue (2018-2034) & (US$ Million)
Figure 58. Russia Amyotrophic Lateral Sclerosis (ALS) Revenue (2018-2034) & (US$ Million)
Figure 59. China Amyotrophic Lateral Sclerosis (ALS) Sales Quantity Market Share by Company in 2022
Figure 60. China Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Company in 2022
Figure 61. China Amyotrophic Lateral Sclerosis (ALS) Sales Quantity Market Share by Type (2018-2034)
Figure 62. China Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Type (2018-2034)
Figure 63. China Amyotrophic Lateral Sclerosis (ALS) Sales Quantity Market Share by Application (2018-2034)
Figure 64. China Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Application (2018-2034)
Figure 65. APAC Amyotrophic Lateral Sclerosis (ALS) Sales Quantity Market Share by Company in 2022
Figure 66. APAC Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Company in 2022
Figure 67. APAC Amyotrophic Lateral Sclerosis (ALS) Sales Quantity Market Share by Type (2018-2034)
Figure 68. APAC Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Type (2018-2034)
Figure 69. APAC Amyotrophic Lateral Sclerosis (ALS) Sales Quantity Market Share by Application (2018-2034)
Figure 70. APAC Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Application (2018-2034)
Figure 71. APAC Amyotrophic Lateral Sclerosis (ALS) Revenue Share by Region (2018-2034)
Figure 72. APAC Amyotrophic Lateral Sclerosis (ALS) Sales Quantity Share by Region (2018-2034)
Figure 73. Japan Amyotrophic Lateral Sclerosis (ALS) Revenue (2018-2034) & (US$ Million)
Figure 74. South Korea Amyotrophic Lateral Sclerosis (ALS) Revenue (2018-2034) & (US$ Million)
Figure 75. China Taiwan Amyotrophic Lateral Sclerosis (ALS) Revenue (2018-2034) & (US$ Million)
Figure 76. Southeast Asia Amyotrophic Lateral Sclerosis (ALS) Revenue (2018-2034) & (US$ Million)
Figure 77. India Amyotrophic Lateral Sclerosis (ALS) Revenue (2018-2034) & (US$ Million)
Figure 78. Middle East, Africa and Latin America Amyotrophic Lateral Sclerosis (ALS) Sales Quantity Market Share by Company in 2022
Figure 79. Middle East, Africa and Latin America Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Company in 2022
Figure 80. Middle East, Africa and Latin America Amyotrophic Lateral Sclerosis (ALS) Sales Quantity Market Share by Type (2018-2034)
Figure 81. Middle East, Africa and Latin America Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Type (2018-2034)
Figure 82. Middle East, Africa and Latin America Amyotrophic Lateral Sclerosis (ALS) Sales Quantity Market Share by Application (2018-2034)
Figure 83. Middle East, Africa and Latin America Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Application (2018-2034)
Figure 84. Middle East, Africa and Latin America Amyotrophic Lateral Sclerosis (ALS) Sales Quantity Share by Country (2018-2034)
Figure 85. Middle East, Africa and Latin America Amyotrophic Lateral Sclerosis (ALS) Revenue Share by Country (2018-2034)
Figure 86. Brazil Amyotrophic Lateral Sclerosis (ALS) Revenue (2018-2034) & (US$ Million)
Figure 87. Mexico Amyotrophic Lateral Sclerosis (ALS) Revenue (2018-2034) & (US$ Million)
Figure 88. Turkey Amyotrophic Lateral Sclerosis (ALS) Revenue (2018-2034) & (US$ Million)
Figure 89. Israel Amyotrophic Lateral Sclerosis (ALS) Revenue (2018-2034) & (US$ Million)
Figure 90. GCC Countries Amyotrophic Lateral Sclerosis (ALS) Revenue (2018-2034) & (US$ Million)
Figure 91. Amyotrophic Lateral Sclerosis (ALS) Value Chain
Figure 92. Amyotrophic Lateral Sclerosis (ALS) Production Process
Figure 93. Channels of Distribution (Direct Vs Distribution)
Figure 94. Distributors Profiles
Figure 95. Bottom-up and Top-down Approaches for This Report
Figure 96. Data Triangulation
Figure 97. Key Executives Interviewed